1. Home
  2. CRBU vs NSPR Comparison

CRBU vs NSPR Comparison

Compare CRBU & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBU
  • NSPR
  • Stock Information
  • Founded
  • CRBU 2011
  • NSPR 2005
  • Country
  • CRBU United States
  • NSPR United States
  • Employees
  • CRBU N/A
  • NSPR N/A
  • Industry
  • CRBU Medicinal Chemicals and Botanical Products
  • NSPR Medical/Dental Instruments
  • Sector
  • CRBU Health Care
  • NSPR Health Care
  • Exchange
  • CRBU Nasdaq
  • NSPR Nasdaq
  • Market Cap
  • CRBU 93.0M
  • NSPR 75.1M
  • IPO Year
  • CRBU 2021
  • NSPR N/A
  • Fundamental
  • Price
  • CRBU $1.62
  • NSPR $2.30
  • Analyst Decision
  • CRBU Strong Buy
  • NSPR Strong Buy
  • Analyst Count
  • CRBU 4
  • NSPR 2
  • Target Price
  • CRBU $8.50
  • NSPR $4.50
  • AVG Volume (30 Days)
  • CRBU 1.9M
  • NSPR 389.2K
  • Earning Date
  • CRBU 08-05-2025
  • NSPR 08-05-2025
  • Dividend Yield
  • CRBU N/A
  • NSPR N/A
  • EPS Growth
  • CRBU N/A
  • NSPR N/A
  • EPS
  • CRBU N/A
  • NSPR N/A
  • Revenue
  • CRBU $9,918,000.00
  • NSPR $7,027,000.00
  • Revenue This Year
  • CRBU $9.52
  • NSPR $4.85
  • Revenue Next Year
  • CRBU N/A
  • NSPR $113.47
  • P/E Ratio
  • CRBU N/A
  • NSPR N/A
  • Revenue Growth
  • CRBU N/A
  • NSPR 8.49
  • 52 Week Low
  • CRBU $0.66
  • NSPR $1.99
  • 52 Week High
  • CRBU $3.00
  • NSPR $3.80
  • Technical
  • Relative Strength Index (RSI)
  • CRBU 70.55
  • NSPR 48.63
  • Support Level
  • CRBU $1.62
  • NSPR $2.12
  • Resistance Level
  • CRBU $1.79
  • NSPR $2.48
  • Average True Range (ATR)
  • CRBU 0.12
  • NSPR 0.14
  • MACD
  • CRBU 0.03
  • NSPR 0.01
  • Stochastic Oscillator
  • CRBU 91.79
  • NSPR 73.47

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Share on Social Networks: